| In vitro models for the prediction of in vivo performance of oral dosage forms ES Kostewicz, B Abrahamsson, M Brewster, J Brouwers, J Butler, ... European Journal of Pharmaceutical Sciences 57, 342-366, 2014 | 399 | 2014 |
| Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems DJ Phillips, SR Pygall, VB Cooper, JC Mann Journal of Pharmacy and Pharmacology 64 (11), 1549-1559, 2012 | 201 | 2012 |
| The design, operation, and application of a dynamic gastric model MJS Wickham, RM Faulks, J Mann, G Mandalari Dissolution Technol 19 (3), 15-22, 2012 | 134 | 2012 |
| In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration J Butler, B Hens, M Vertzoni, J Brouwers, P Berben, J Dressman, ... European Journal of Pharmaceutics and Biopharmaceutics 136, 70-83, 2019 | 117 | 2019 |
| Biopharmaceutical aspects and implications of excipient variability in drug product performance P Zarmpi, T Flanagan, E Meehan, J Mann, N Fotaki European Journal of Pharmaceutics and Biopharmaceutics 111, 1-15, 2017 | 98 | 2017 |
| Validation of dissolution testing with biorelevant media: an OrBiTo study J Mann, J Dressman, K Rosenblatt, L Ashworth, U Muenster, K Frank, ... Molecular pharmaceutics 14 (12), 4192-4201, 2017 | 88 | 2017 |
| Industry's view on using quality control, biorelevant, and clinically relevant dissolution tests for pharmaceutical development, registration, and commercialization H Grady, D Elder, GK Webster, Y Mao, Y Lin, T Flanagan, J Mann, ... Journal of pharmaceutical sciences 107 (1), 34-41, 2018 | 83 | 2018 |
| Biopharmaceutical understanding of excipient variability on drug apparent solubility based on drug physicochemical properties. Case study: Superdisintegrants P Zarmpi, T Flanagan, E Meehan, J Mann, N Fotaki The AAPS journal 22, 1-17, 2020 | 45 | 2020 |
| Exploring the performance-controlling tablet disintegration mechanisms for direct compression formulations N Maclean, E Walsh, M Soundaranathan, I Khadra, J Mann, H Williams, ... International Journal of Pharmaceutics 599, 120221, 2021 | 44 | 2021 |
| Biorelevant dissolution testing of a weak base: Interlaboratory reproducibility and investigation of parameters controlling in vitro precipitation P Berben, L Ashworth, S Beato, J Bevernage, JL Bruel, J Butler, ... European Journal of Pharmaceutics and Biopharmaceutics 140, 141-148, 2019 | 41 | 2019 |
| Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions … XJH Pepin, AJ Moir, JC Mann, NJ Sanderson, R Barker, E Meehan, ... European journal of pharmaceutics and biopharmaceutics 142, 435-448, 2019 | 37 | 2019 |
| Recommended strategies for the oral administration of paediatric medicines with food and drinks in the context of their biopharmaceutical properties: a review J Martir, T Flanagan, J Mann, N Fotaki Journal of Pharmacy and Pharmacology 69 (4), 384-397, 2017 | 35 | 2017 |
| The relationship between redox enzyme activity and electrochemical potential—cellular and mechanistic implications from protein film electrochemistry AJ Gates, GL Kemp, CY To, J Mann, SJ Marritt, AG Mayes, DJ Richardson, ... Physical Chemistry Chemical Physics 13 (17), 7720-7731, 2011 | 35 | 2011 |
| Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input XJH Pepin, NJ Sanderson, A Blanazs, S Grover, TG Ingallinera, JC Mann European Journal of Pharmaceutics and Biopharmaceutics 142, 421-434, 2019 | 33 | 2019 |
| Toward biorelevant dissolution: application of a biphasic dissolution model as a discriminating tool for HPMC matrices containing a model BCS class II drug DJ Phillips, SR Pygall, VB Cooper, JC Mann Dissolution Technol 19 (1), 25-34, 2012 | 29 | 2012 |
| Impact of magnesium stearate presence and variability on drug apparent solubility based on drug physicochemical properties P Zarmpi, T Flanagan, E Meehan, J Mann, N Fotaki The AAPS journal 22, 1-18, 2020 | 28 | 2020 |
| Impact of acid-reducing agents on gastrointestinal physiology and design of biorelevant dissolution tests to reflect these changes D Segregur, T Flanagan, J Mann, A Moir, EM Karlsson, M Hoch, D Carlile, ... Journal of pharmaceutical sciences 108 (11), 3461-3477, 2019 | 28 | 2019 |
| A formulation case study comparing the dynamic gastric model with conventional dissolution methods JC Mann, SR Pygall Dissolution Technol 19 (4), 14-19, 2012 | 27 | 2012 |
| The effect of reduced gastric acid secretion on the gastrointestinal disposition of a ritonavir amorphous solid dispersion in fasted healthy volunteers: an in vivo-in vitro … J Van Den Abeele, C Kostantini, R Barker, A Kourentas, JC Mann, ... European journal of pharmaceutical sciences 151, 105377, 2020 | 21 | 2020 |
| Tablet disintegration performance: effect of compression pressure and storage conditions on surface liquid absorption and swelling kinetics D Markl, N Maclean, J Mann, H Williams, A Abbott, H Mead, I Khadra International Journal of Pharmaceutics 601, 120382, 2021 | 18 | 2021 |
Nikoletta FotakiProfessor of Biopharmaceutics, University of Bath, UKVerifierad e-postadress på bath.ac.uk
